271980.KS
Jeil Pharmaceutical Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 10,780.00
−1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 543.5B | 566.3B | 704.5B | 726.4B | 722.2B |
| Cost of Revenue | 326.6B | 358.9B | 527.0B | 542.1B | 565.4B |
| Gross Profit | 212.4B | 208.4B | 177.5B | 184.3B | 156.8B |
| Operating Expenses | |||||
| R&D Expense | 59.1B | 45.0B | 38.8B | 45.7B | 41.1B |
| SG&A Expense | 111.4B | 87.9B | 82.8B | 76.5B | 74.6B |
| General & Admin Expense | 29.0B | 36.6B | 35.3B | 33.5B | 30.8B |
| Selling & Marketing Expense | 37.7B | 51.3B | 47.5B | 43.0B | 43.9B |
| Other Expenses | 57.5B | 55.2B | 74.9B | 53.3B | 54.4B |
| Total Operating Expenses | 213.6B | 188.1B | 196.4B | 175.5B | 170.1B |
| Cost and Expenses | 540.3B | 545.6B | 723.5B | 717.7B | 735.6B |
| Operating Income (EBIT) | 3.0B | 20.3B | (18.9B) | 8.7B | (13.5B) |
| Non-Operating | |||||
| Interest Income | 1.7B | 1.6B | 1.2B | 1.0B | 115.6M |
| Interest Expense | 4.7B | 4.4B | 5.1B | 6.0B | 3.0B |
| Net Interest Income | (2.9B) | (2.8B) | (3.9B) | (5.0B) | (2.9B) |
| Other Non-Op Income/Expense | 15.7B | 14.3B | (8.6B) | (6.8B) | 257.7M |
| Non-Operating Income (excl Interest) | (18.2B) | — | 3.0B | 782.3M | (5.3B) |
| EBT (Pre-Tax Income) | 18.7B | 35.0B | (27.5B) | 1.9B | (13.2B) |
| Income Tax Expense | (3.2B) | 2.9B | 3.2B | (3.3B) | 1.8B |
| Bottom Line | |||||
| Net Income | 9.3B | 23.4B | (30.0B) | 5.0B | (13.1B) |
| Earnings from Cont. Ops | 21.9B | 32.0B | (30.7B) | 5.2B | (15.0B) |
| Earnings from Discont. Ops | — | — | — | — | 142.2M |
| Bottom Line Net Income | 9.3B | 23.4B | (30.0B) | 5.0B | (13.1B) |
| Per Share | |||||
| Basic EPS | ₩1,216 | ₩1,605 | (₩2,056) | ₩343 | (₩898) |
| Diluted EPS | ₩644 | ₩1,605 | (₩2,056) | ₩343 | (₩898) |
| Revenue Per Share | ₩36,960 | ₩38,513 | ₩48,349 | ₩49,849 | ₩49,553 |
| Shares | |||||
| Basic Shares Outstanding | 14.7M | 14.7M | 14.6M | 14.6M | 14.6M |
| Diluted Shares Outstanding | 14.7M | 14.7M | 14.6M | 14.6M | 14.6M |
| Profitability Metrics | |||||
| EBITDA | 24.8B | 32.6B | (10.6B) | 17.7B | (1.2B) |
| D&A | 12.9B | 12.3B | 11.3B | 9.8B | 8.9B |
| EBIT | 12.0B | 20.3B | (21.9B) | 7.9B | (10.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026